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Abstract
Treatment of stage II–IV nonseminomatous testicular germ cell tumors (NSTGCTs) consists of cisplatin-based combination
chemotherapy and, when present, resection of residual retroperitoneal tumor mass (RRTM) by conventional laparotomy or
laparoscopy. In case of a retroperitoneal recurrence, a second conventional or laparoscopic procedure may be challenging.
A case of late relapse after prior conventional resection of a RRTM and tailor-made surgical management with a posterior
retroperitoneoscopic resection (PRR) is reported. A posterior retroperitoneoscopic RRTM resection was performed in a 26-year-
old male with a history of stage IIC NSTGCT, presenting with a late left-sided retroperitoneal relapse, 6 years after initial
treatment. Postoperative course was uneventful and at 1-year follow-up the patient had no evidence of disease. Reoperative
surgery by a minimal invasive retroperitoneoscopic approach should be considered as an alternative for patients with a
recurrent retroperitoneal tumor mass of a NSTGCT.
INTRODUCTION
Cisplatin-based combination chemotherapy followed by com-
plete resection of residual masses is the cornerstone of advanced
nonseminomatous testicular germ cell tumor (NSTGCT) treat-
ment (Fig. 1) [1, 2]. In 8% of NSTGCT patients treated by
chemotherapy and adjunctive surgery, recurrent disease is
encountered [3]. In the case of a growing teratoma, resection
is performed, whereas in the case of presumed vital tumor,
initial treatment will be chemotherapy followed by resection
of residual tumor mass if indicated [4].
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Relapses after prior conventional resections of residual
retroperitoneal tumor mass (RRTM) are usually located in the
retroperitoneum requiring a laparotomy with extensive surgical
exploration. In this case report, an alternative surgical approach,
the posterior retroperitoneoscopic resection (PRR), is described.
CASE REPORT
A 26-year-old man was first diagnosed in 2008 with a left-sided
testicular tumor treated with inguinal orchiectomy. Resection
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Figure 1: Summary of primary treatment of high stage NSTGCT.
teratoma. The patient, with stage IIC NSTGCT and intermediate-
risk group according to International Germ Cell Cancer Col-
laborative Group [5], received four courses of cisplatin-based
chemotherapy. Restaging procedures revealed normalized
alpha-fetoprotein (AFP) and a normal beta-human chorionic
gonadotropin < 1 U/L. Furthermore, CT scan of the thorax and
abdomen showed a left-sided retroperitoneal para-aortic tumor
mass, situated caudally of the renal hilus, measuring 6 × 7 cm
(prior 5 × 5 cm), and a second retroperitoneal mass situated
interaortocaval measuring 1.7 × 1.9 cm (prior 2.6 × 3 cm) (Fig. 2A).
Subsequently, the patient underwent a midline laparotomy to
resect these tumor masses. Surgical specimens consisted of
R0 resection with fibrotic tissue and teratoma with mature
and immature compounds. Due to a lack of patient adherence,
follow-up protocol could not be executed.
He presented himself 6 years later with a request to resume
follow-up, in the absence of symptoms. A retroperitoneal recur-
rence located at the left retrocrural space with a diameter of
17 mm (Fig. 2B) with normal tumor markers was diagnosed
87 months after initial resection of RRTM. The recurrence, sug-
gestive for a growing teratoma, was located far from the previous
operative resection area. The patient was discussed in the multi-
disciplinary tumor board and offered a posterior retroperitoneo-
scopic resection of the recurrent disease with the highest chance
of a complete resection of this late relapse without surgically
dealing with scarred tissues and adhesions caused by a former
operation field.
The surgical procedure was performed by two surgical oncol-
ogists with experience in performing posterior retroperitoneo-
scopic adrenalectomy (PRA) [6]. The procedure was performed
with the patient in prone position and the surgeon positioned
ipsilateral to the tumor and the assistant at the opposite site. The
first part of the surgery involved introduction and developing
sufficient retroperitoneal space. A first incision was made below
the tip of the 12th rib, eventually serving as camera port, and
the second port was then placed without camera view on the
index finger (Fig. 3). Pneumoperitoneum was created with a high
pressure of 25 mm Hg. After having created enough working
space, a third 10-mm port was placed. After mobilizing the
left kidney from its surroundings and laterally, the tumor mass
could be identified. Tumor resection was performed according to
the same oncological principles as in conventional resection of
RRTM excising only the visible abnormal retroperitoneal tumor
mass. Proximal dissection was carefully performed around the
left renal artery and vein. The tumor was gently separated off
the aorta by blunt and sharp dissection. Finally, the surgical
specimen was placed in an endoscopy bag and extracted from
the extraperitoneal cavity. The procedure time was 120 minutes.
No intraoperative complications occurred. The patient was dis-
charged the next day. Resection specimen showed a R0 resection
of a retroperitoneal tumor mass with remnants of mature ter-
atoma. During 12-month follow-up, the patient had no evidence
of disease with normal tumor markers and normal imaging
(Fig. 4).
DISCUSSION
At the UMCG, the current relapse rate in advanced NSTGCT
patients treated with cisplatin-based combination chemother-
apy and, if indicated, resection residual disease is 18% [7]. His-
tology shows that teratoma is often present in late relapses and
reoperative surgery [7]. Since teratomas are unresponsive to both
chemotherapy and radiotherapy, complete resection of all resid-
ual tumor masses is an essential part of the combined treatment
of NSTGCTs [4]. Since these retroperitoneal relapses tend to be
chemoresistant, a selection of patients with anatomically well-
defined retroperitoneal disease require reoperative retroperi-
toneal surgery. Redo surgeries can be technically challenging
because of postchemotherapy desmoplastic reaction and anni-
hilated and scarred surgical tissue planes with dense adhesions
due to prior surgery [8–10]. Long-term survival varies from 63to
91.3%; factors such as recurrence histology, possibility of salvage
chemotherapy, anatomical site of recurrence and experience of
the surgical oncologist can explain this wide variance in survival
rates [10]. The literature concerning reoperative retroperitoneal
surgery in NSTGCTs is limited.
Majority of retroperitoneal recurrences are located in the
para-aortic mostly left-sided and interaortocaval regions,
making reoperative retroperitoneal surgery challenging [10].
Patients who are candidates for resection of recurrent disease
should first undergo accurate staging with CT abdomen and
chest and MRI, or even PET-CT might be required. This way,
patients with extra-abdominal and non-retroperitoneal disease
that cannot be surgically cured are excluded. The surgical
goal should always be a R0 resection meaning to resect all
abnormal tissues. Pedrosa et al. declared 27% of NSTGCTs
patients with a relapse even unresectable after attempting redo
surgery [10].
In the current patient, technical challenges were taken into
account upfront. Residual tumor mass was situated at a diffi-
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Figure 2: (A) CT scan showing two retroperitoneal masses. (B) CT scan showing retroperitoneal recurrence..
Figure 3: Schematic positioning of a patient in the prone position during the
retroperitoneoscopic procedure to excise the RRTM. ∗Arrow is directed at the port
positions; in the middle the camera port is shown.
Figure 4: CT scan postoperatively. ∗Arrow is directed at the adrenal which was
not damaged during the procedure.
and confidence gained from the PRA, decision was made to
perform a PRR instead of a conventional midline laparotomy.
Thus, the previous transabdominal surgical route was bypassed,
and surgery could be performed partially in a ‘virgin’ territory
creating significantly less morbidity.
Today still most of the surgical resections for recurrent
NSTGCTs are performed through a conventional midline or
transverse exposure. The retroperitoneoscopic technique as
used for adrenalectomy might be an alternative option. However,
PRR requires a substantial learning time and is technically
challenging [6].
CONCLUSION
In reoperative retroperitoneal surgery in NSTGCTs, an alter-
native surgical strategy such as PRR can avoid the impact of
extended conventional surgery or relaparoscopy on the abdom-





There is an ethics approval and consent to participate consent
for publication of data and material.
COMPETING INTERESTS
All authors have no competing interests.
FUNDING
There is no funding that was used for this report.
AUTHORS’ CONTRIBUTIONS
See specific form also submitted.
CONTRIBUTION AUTHOR(S)
Study concepts: Öztürk C., Hoekstra H.J., Hemmer P.H., Gietema








roningen user on 23 Septem
ber 2020
4 Ç. Öztürk et al.
P.H., Gietema J.A., and Kruijff S. Data acquisition: does not apply.
Quality control of data and algorithms: does not apply. Data
analysis and interpretation: does not apply. Statistical analysis:
does not apply. Manuscript preparation: Öztürk C., Hoekstra H.J.,
Hemmer P.H., Gietema J.A., and Kruijff S. Manuscript editing:
Öztürk C., Hoekstra H.J., Hemmer P.H., Gietema J.A., and Kruijff
S. Manuscript review: Öztürk C., Hoekstra H.J., Hemmer P.H.,
Gietema J.A., and Kruijff S.






NAME OF PRINCIPAL INVESTIGATOR
Ozturk (If funded, please include a statement as to the role of the
study sponsor at end of manuscript under a heading ‘Role of the
Funding Source’).
POSSIBLE CONFLICT OF INTEREST
No.
‘All the authors have made a significant contribution to this
manuscript, have seen and approved the final manuscript and
have agreed to its submission to the BMC Urology’.
REFERENCES
1. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ,
Mulder PH, Koops HS, et al. Improved long term sur-
vival of patients with metastatic nonseminomatous testic-
ular germ cell carcinoma in relation to prognostic classi-
fication systems during the cisplatin era. Cancer 2001;91:
1304–15.
2. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa
SD. Postchemotherapy retroperitoneal surgery remains nec-
essary in patients with nonseminomatous testicular can-
cer and minimal residual tumor masses. J Clin Oncol
2003;21:3310–7.
3. Heidenreich P. Retroperitoneal lymphadenectomy and
resection for testicular cancer: an update on best practice.
Ther Adv Urol 2012;4:187–205.
4. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-
Cedermark G, Fizazi K, et al. EAU guidelines on testicular
cancer: 2011 update; European Association of Urology. Eur
Urol 2011;60:304–19.
5. International Germ Cell Cancer Collaborative Group. Inter-
national germ cell consensus classification: a prognostic
factor-based staging system for metastatic germ cell can-
cers. J Clin Oncol 1997;15:594–603.
6. Vrielink OM, Hemmer PH, Kruijff S. Considerations in min-
imally invasive adrenal surgery; the frontdoor or the back-
door? Minerva Chir 2018;73:93–9.
7. Ozturk C, Been LB, van Ginkel RJ, Gietema JA, Hoekstra
HJ. Laparoscopic resection of residual retroperitoneal tumor
mass in advanced Nonseminomatous testicular germ cell
Tumors; a feasible and safe oncological procedure. Sci Rep
2019;9:15837.
8. Heidenreich A, Ohlmann C, Hegele A, Beyer J. Repeat
retroperitoneal lymphadenectomy in advanced testicular
cancer. Eur Urol 2005;47:64–71.
9. McKiernan JM, Motzer RJ, Bajorin DF, Bacik GJ, Sheinfeld J.
Reoperative retroperitoneal surgery for nonseminomatous
germ cell tumor: clinical presentation, patterns of recur-
rence, and outcome. Urologia 2003;62:732–6.
10. Pedrosa JA, Masterson TA, Rice KR, Bihrle R, Beck SD, Foster
RS. Reoperative retroperitoneal lymph node dissection for
metastatic germ cell tumors: analysis of local recurrence








roningen user on 23 Septem
ber 2020
